Clinical trials: Hyperlipoproteinemia (a)
Overweight and Obesity, NAFLD
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .
- Conditions
- Overweight and Obesity, NAFLD, Hyperlipidemia
- Trial name
- NCT04686994
- Testing
- ASC 41
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Combined Hyperlipidemia
"Phospholipovit" vs Placebo in Patients With Combined Hyperlipidemia
"Phospholipovit" vs placebo in patients with combined hyperlipidemia
- Trial name
- NCT05742022
- Testing
- "Phospholipovit"
- Where
- 3 sites in Russia
- Volunteers
- 100 people
- Sponsor
- Institute of Biomedical Chemistry, Russia
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI
- Trial name
- C-STAR (NCT05661552)
- Testing
- Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Yonsei University
Familial Hypercholesterolemia
Cascade Testing In Identifying At-risk Family Members Of Individuals With Familial Hypercholesterolemia (FH) In PCP
The purpose of this study is to evaluate the effectiveness of two models of cascade testing in identifying at-risk family members of individuals diagnosed with familial hypercholesterolemia (FH).
- Trial name
- NCT07653555
- Testing
- Cascade testing, Standard of Care
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Mayo Clinic
Hyperlipoproteinemia(a)
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany
Phase III study to test the hypothesis that treatment with pelacarsen (TQJ230) 80 mg Q4W compared to placebo significantly reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia (a) and established…
- Trial name
- NCT05305664
- Testing
- Pelacarsen (TQJ230) 80 mg s.c.
- Where
- 13 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Hyperlipidemia, Hypercholesterolemia
A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)
The purpose of this study is to assess the cholesterol lowering effects of an investigational drug in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).
- Conditions
- Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT00093899
- Testing
- ezetimibe (+) simvastatin
- Volunteers
- 611 people
- Sponsor
- Organon and Co
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet
The purpose of this study is to determine the efficacy and safety of topiramate compared with placebo in obese, Type 2 diabetic patients on a controlled diet.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231530
- Testing
- topiramate
- Volunteers
- 541 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hyperlipidemia
Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C
Study to evaluate the pharmacokinetics and pharmacodynamics of inclisiran treatment given as single subcutaneous injection in Chinese participants with elevated low-density lipoprotein cholesterol (LDL-C) despite treatment with…
- Trial name
- ORION-14 (NCT04774003)
- Testing
- 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Hyperlipidemia
Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects
This study is to evaluate the safety, tolerability, pharmacokinetics of DC371739 after a single-dose oral administration in healthy Chinese subjects, and to explore the maximum tolerated dose, also the pharmacokinetics of urine…
- Trial name
- NCT04640012
- Testing
- DC371739
- Where
- China
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Acne Vulgaris, Allergic Rhinitis
MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use
The specific aim of this proposed pilot study is to compare two standardized processes (paper and electronic) to deliver a customized MedlinePlus health information prescription.
- Conditions
- Acne Vulgaris, Allergic Rhinitis, Anxiety, Asthma
- Trial name
- NCT01050465
- Testing
- health information prescription
- Volunteers
- 907 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Hyperlipidemia
Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline in LDL-C when used as…
- Trial name
- MENDEL (NCT01375777)
- Testing
- Evolocumab, Ezetimibe
- Where
- 58 sites in United States, Australia and 3 more
- Volunteers
- 411 people
- Sponsor
- Amgen
Primary Hypercholesterolemia or Mixed Hyperlipidemia
A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan
Cardiovascular disease (CVD) is a chronic non-communicable disease among the most common causes of death worldwide. Substantial reductions in risks of CVD can be achieved through the management of modifiable risk factors…
- Trial name
- CLEAR Taiwan (NCT06925100)
- Testing
- Bempedoic acid 180 mg tablet
- Where
- 3 sites in Taiwan
- Volunteers
- 180 people
- Sponsor
- Daiichi Sankyo
Diabetes Mellitus, Type 2, Hyperlipidemia
A Brief Intervention to Improve Medication Knowledge and Adherence Among Family Medicine Patients in South Texas
This study examines a brief physician counseling intervention to improved medication knowledge and compliance in family medicine patients who have diabetes, hypertension or high cholesterol.
- Conditions
- Diabetes Mellitus, Type 2, Hyperlipidemia, Hypertension
- Trial name
- NCT00846300
- Testing
- Physician counseling for health behavior change
- Where
- 6 sites in United States
- Volunteers
- 150 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Ischemic Stroke
Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo)
Carotid ultrasound can reveal the intima-media complex thickness(IMT), that has been reported to be a marker of atherosclerosis as well as a risk of cardiovascular events, and to be attenuated by…
- Trial name
- NCT00361530
- Testing
- Statin
- Where
- 2 sites in Japan
- Volunteers
- 854 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Hypercholesterolemia, Hyperlipoproteinemia Type II
Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia
The purpose of the first part of this study is to determine the safety and tolerability of a single dose of AEM-28, an apolipoprotein E mimetic, in subjects with high total cholesterol who are otherwise healthy subjects.
- Trial name
- NCT02100839
- Testing
- AEM-28, Normal Saline
- Where
- Australia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- LipimetiX Development, LLC
Hyperlipidemia, Pregnancy
Lipid Profile as Predictor of Adverse Maternal and Neonatal Outcomes: A Pilot Study
The purpose of this study is to ascertain lipid profiles during pregnancy, specifically during the 24-28 week gestation and again near term at 36 weeks gestation.
- Trial name
- NCT05535660
- Testing
- Lipid panel
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Familial Hypercholesterolemia
Improving Identification of Familial Hypercholesterolaemia in Primary Care (FAMCAT)
Multi-centre, non-randomised, non-controlled quasi-experimental study with nested qualitative study and economic appraisal. Improving the identification of patients at high risk of cardiovascular disease in primary care, caused…
- Trial name
- FAMCAT (NCT03934320)
- Testing
- FAMCAT
- Where
- United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Hyperlipidemia
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy
- Trial name
- NCT00559962
- Testing
- AEGR-733, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate
- Where
- 15 sites in United States
- Volunteers
- 260 people
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Hyperlipidaemia, Hyperlipidemia
Nigella Sativa Supplementation in Hyperlipidemia Treatment
Hyperlipidemia is defined as an elevation of plasma cholesterol, lipid, or lipoprotein levels above normal due to abnormal fat metabolism or function, and individuals with hyperlipidemia are approximately twice as likely to…
- Trial name
- NCT06890546
- Testing
- Nigella Sativa Oil capsule, Diet
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Istanbul Bilgi University
Familial Hypercholesterolemia
Familial Hypercholesterolemia Interpretive Comment - Nudging to Detection.
Familial hypercholesterolemia is the most common inherited disease of the lipid metabolism, however it remains underdiagnosed. Only 15 % of 30.000 possible patients have been found in Denmark.
- Trial name
- FIND (NCT05614219)
- Testing
- Biochemistry interpretive comment on elevated LDL-C levels
- Where
- 2 sites in Denmark
- Volunteers
- 2,000 people
- Sponsor
- Odense University Hospital